PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...

Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Over the past decade, non-viral DNA template delivery has been used with engineered nucleases to target single-stranded DNA sequences in hematopoietic stem and progenitor cells (HSPCs). While ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

AUSTIN, Texas, June 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...

An enduring challenge for the commercialization of genetic therapies is delivering the therapeutic molecules to the proper destination within the body. Viruses are natural delivery systems for nucleic ...

Heart diseases are still the number one cause of death worldwide. According to the World Health Organization, cardiovascular diseases led to the deaths of about 9.8 million people in 2022 alone, ...

A team led by Professor Shoichiro Asayama at Tokyo Metropolitan University has synthesized a charge-free molecule designed to sneak plasmid DNA into living cells via hydrogen bonding, dramatically ...

Allied Market Research published a report, titled, "Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral ...